A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease, Re-admission, Acute, blood disorders, hemoglobin, red blood cells, RBCs, sickle-like shape, mutation in hemoglobin gene, sickle-cell trait, sickle-cell crisis, SCD, VOC, SCA, Anemia, Sickle Cell, Inclacumab, inclacumab 30 mg/kg
Lead Scientist at UCSF
- Elliott Vichinsky
I am the Director of Hematology/Oncology at UCSF Benioff Children's Hospital Oakland, Adjunct Professor at University of California San Francisco, as well as the Director of the Northern California Sickle Cell and Thalassemia Centers. I am a board-certified pediatric hematologist/oncologist with a major interest in understanding and improving the care of patients with hemoglobinopathies.